RxDoctor Payments Data

Michael Creer, MD

Clinical Pathology · Hershey, PANPI 1568476042

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,050 of the $4,178 with a category attached, or 96.9%. Abbott accounts for 96.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $4,050 and has fallen 97.3% since, to $110 in 2025.

$4,178in general payments, 2019–2025

Across 3 payments — averaging $1392.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • AstraZeneca$110
  • Hemosonics LLC$18
$5,672,175in research payments, 2019–2025

Across 982 payments — averaging $5776.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$5.7M
  • Radiometer America, Inc$20K

What the payments were for

  • Consulting fees$4,05097%
  • Food & beverage$1283%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott1$4,050
AstraZeneca1$110
Hemosonics LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical pathology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,137
Medicare patients
386
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →